Background : Epidermal growth factor receptor (EGFR) mutation status is a good predictor of response to EGFR tyrosine kinase inhibitors (TKI) in non-small cell lung cancer (NSCLC). The existing data on the difference in survival outcome between
Search Results
HSR22-144: Survival Difference of EGFR Exon 19 Deletion and Exon 21 Mutation in Asian Patients With Advanced Non-small Cell Lung Cancer
Dawn Lynn P Guardiario, Gerardo H. Cornelio, and Raiza S. Marave
EGFR-Mutated Lung Cancer With T790M-Acquired Resistance in the Brain and Histologic Transformation in the Lung
Kevin S. Scher, Juan-Sebastian Saldivar, Michael Fishbein, Alberto Marchevsky, and Karen L. Reckamp
/print certificate. Release date: September 19, 2013; Expiration date: September 19, 2014. Learning Objectives Upon completion of this activity, participants will be able to: Explain a potential resistance mechanism to EGFR-TKI therapy when used to
HSR23-111: Real-World EGFR Testing in Patients With Surgically Resected Stage I-III Non–Small Cell Lung Cancer (NSCLC) in US Community Oncology Practices
Anne Shah, Jon Apple, Joanne Willey, Michael Ayars, Daniel Simmons, Dana Nickleach, Ganiat Mumuney, Manish Patel, and Kristen Brunskill
25 Nov 2020 to encourage testing for EGFR mutations in eligible patients with resectable NSCLC. This study evaluated real-world testing for EGFR, including the impact of guideline changes (before vs after 25 Nov 2020) on testing in the US community
HSR21-069: Factors Associated With Time to Treatment With an EGFR-TKI Among Patients With Non-Squamous Metastatic Non-Small Cell Lung Cancer: A SEER-Medicare Analysis
Chunlin Qian, Elizabeth Marrett, Winghan Jacqueline Kwong, and Laura Q.M. Chow
Background: First-line targeted therapy with an EGFR-TKI inhibitor for metastatic non-small cell lung cancer (mNSCLC) harboring a sensitizing EGFR oncogenic driver mutation demonstrated efficacy and improvements in survival in clinical trials and
CLO24-092: Neoadjuvant Tyrosine Kinase Inhibitors (TKIs) Efficacy in EGFR Positive Stage III Non–Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
John Kelvin Lalusis and John Lois Padayao
clinical outcomes of TKIs in the adjuvant and metastatic setting among patients with EGFR mutant NSCLC, a number of prospective trials have explored the efficacy of TKI as neoadjuvant treatment, however, results of these studies were inconsistent in terms
HSR23-090: Racial Differences in Outcomes of Osimertinib in Patients With EGFR-Positive Non–Small Cell Lung Cancer in a Real World US Population
Jeffrey Zhong, Jaime Abe Perez, Annie Liang Zhang, Debora Bruno, and Melinda Laine-Hsu
Background: Osimertinib is the current first-line treatment for metastatic EGFR-mutation positive Non–Small Cell lung cancer (NSCLC). Available data suggests osimertinib is less effective in Asian patients with EGFR-mutation positive NSCLC when
HSR22-173: Treatment Patterns, Healthcare Resource Use and Costs Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer Following Discontinuation of Osimertinib and Platinum-Based Chemotherapy
Julie Vanderpoel, Bruno Emond, Isabelle Ghelerter, Katherine Milbers, Marie-Hélène Lafeuille, Patrick Lefebvre, and Lorie A Ellis
Background : EGFR tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib (OSI) have become the first-line standard of care (SOC) for patients with non-small cell lung cancer (NSCLC) and epidermal growth factor receptor mutations (EGFRm
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers
Helena A. Yu and Gregory J. Riely
Epidermal Growth Factor Receptors The epidermal growth factor receptor (EGFR) family includes 4 receptor tyrosine kinases: EGFR (HER1), ERBB2 (HER2), ERBB3 (HER3), and ERBB4 (HER4). The EGFR is composed of an extracellular ligand binding
HSR24-124: Determinants of Quality of Life and Optimism in Patients With EGFR Mutated Advanced Non–Small Cell Lung Cancer
Elizabeth Marrett, Shaloo Gupta, Kushal Modi, Song Li, Jillian Rowen, and Jackie Kwong
regimen (2L-CHEMO). Methods: A cross-sectional, online survey of patients with self-reported advanced or metastatic EGFR-mutated NSCLC was conducted between Nov 2022 and Jan 2023. Descriptive statistics were used to summarize patient responses
Biomarker Use in Colorectal Cancer Therapy
Robin K. Kelley, Grace Wang, and Alan P. Venook
that an activating mutation in the KRAS oncogene is a biomarker for tumor resistance to monoclonal antibodies targeting the epidermal growth factor receptor (EGFR); this has led to the widespread adoption of tumor KRAS mutational analysis before
